checkAd

     131  0 Kommentare Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin in Diffuse Large B Cell Lymphoma - Seite 3

    This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

    This information was brought to you by Cision http://news.cision.com

    Lesen Sie auch

    https://news.cision.com/nordic-nanovector/r/nordic-nanovector-completes-patient-enrolment-into-phase-1-trial-of-betalutin--in-diffuse-large-b-ce,c3246599


    PR Newswire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3
    Verfasst von PR Newswire (engl.)
    Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin in Diffuse Large B Cell Lymphoma - Seite 3 OSLO, Norway, Dec. 1, 2020 /PRNewswire/ - Nordic Nanovector ASA (OSE: NANO) announces that it has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin (177Lu lilotomab satetraxetan) in patients with relapsed/refractory …